{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:53:12Z","timestamp":1791913992658,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100017691","name":"Guangxi Key Research and Development Program","doi-asserted-by":"publisher","award":["GuiKe AB24010082"],"award-info":[{"award-number":["GuiKe AB24010082"]}],"id":[{"id":"10.13039\/501100017691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011827","name":"Guangxi Medical University","doi-asserted-by":"publisher","award":["GXMULJZ202403"],"award-info":[{"award-number":["GXMULJZ202403"]}],"id":[{"id":"10.13039\/501100011827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ejso.2026.112199","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:03:25Z","timestamp":1791356605000},"page":"112199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Value of tumor burden score combined with alpha-fetoprotein stratification in transarterial chemoembolization plus tyrosine kinase inhibitors and immune checkpoint inhibitors as triple conversion therapy for patients with initially unresectable hepatocellular carcinoma: a multicenter retrospective study (GUIDANCE010)"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1007-2198","authenticated-orcid":false,"given":"Zhi-Cheng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Long","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Jian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian-Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Rong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Quan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Meng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Shuang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo-Xin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Ling","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-Yuan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Ge","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1494-6396","authenticated-orcid":false,"given":"Jian-Hong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejso.2026.112199_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.ejso.2026.112199_bib2","doi-asserted-by":"crossref","first-page":"18296","DOI":"10.18632\/oncotarget.15433","article-title":"Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: a real-world study","volume":"8","author":"Zhong","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ejso.2026.112199_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.iliver.2024.100112","article-title":"Systematic treatment in unresectable hepatocellular carcinoma: the most concerns","volume":"3","author":"Zhong","year":"2024","journal-title":"Iliver"},{"issue":"2","key":"10.1016\/j.ejso.2026.112199_bib4","first-page":"168","article-title":"Prognostic nutritional index predicts outcomes in hepatocellular carcinoma treated with atezolizumab and Bevacizumab: a propensity score-matched analysis","volume":"14","author":"Kuo","year":"2026","journal-title":"J Clin Transl Hepatol"},{"issue":"10474","key":"10.1016\/j.ejso.2026.112199_bib5","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"issue":"10474","key":"10.1016\/j.ejso.2026.112199_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2026.112199_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(26)00212-8","article-title":"On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial","author":"Kudo","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.ejso.2026.112199_bib8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/HEP.0000000000001229","volume":"82","author":"Yang","year":"2025","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.ejso.2026.112199_bib9","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.3390\/jcm11175075","article-title":"Diagnostic performance of AFP, AFP-L3, or PIVKA-II for hepatitis C virus-associated hepatocellular carcinoma: a multicenter analysis","volume":"11","author":"Liu","year":"2022","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.ejso.2026.112199_bib10","doi-asserted-by":"crossref","first-page":"e1723","DOI":"10.1093\/oncolo\/oyae139","article-title":"Prognostic significance of postoperative serological incomplete conversion of AFP and PIVKA-II after hepatic resection for hepatocellular carcinoma: a multicenter analysis of 1755 patients","volume":"29","author":"Wang","year":"2024","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ejso.2026.112199_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.iliver.2024.100109","article-title":"Tumor burden score and alpha-fetoprotein level predict prognosis of patients with unresectable hepatocellular carcinoma treated with tyrosine kinase inhibitor and anti-PD-1 antibody","volume":"3","author":"Tang","year":"2024","journal-title":"Iliver"},{"issue":"11","key":"10.1016\/j.ejso.2026.112199_bib12","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.3390\/cancers12113372","article-title":"Using hepatocellular carcinoma tumor burden score to stratify prognosis after liver transplantation","volume":"12","author":"Moris","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ejso.2026.112199_bib13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/SLA.0000000000002064","article-title":"The tumor burden score: a new \"Metro-ticket\" prognostic tool for colorectal liver metastases based on tumor size and number of tumors","volume":"267","author":"Sasaki","year":"2018","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.ejso.2026.112199_bib14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/17474124.2023.2196403","article-title":"Comparison of survival rates as predicted by total tumor volume or tumor burden score in patients with hepatocellular carcinoma concurrent with fatty liver disease and hepatitis B virus","volume":"17","author":"Li","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.ejso.2026.112199_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejso.2026.112199_bib16","first-page":"687","article-title":"Survival benefit of hepatectomy after complete or partial response to conversion therapy in unresectable hepatocellular carcinoma (GUIDANCE003): a multicenter study","volume":"14","author":"Yang","year":"2025","journal-title":"Liver Cancer"},{"issue":"11","key":"10.1016\/j.ejso.2026.112199_bib17","article-title":"Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004)","volume":"7","author":"Yang","year":"2025","journal-title":"JHEP Rep"},{"issue":"4","key":"10.1016\/j.ejso.2026.112199_bib18","first-page":"592","article-title":"Prognostic usefulness of clinical complete response after PD-1 inhibitor-based combination therapy for unresectable hepatocellular carcinoma (GUIDANCE006)","volume":"15","author":"Ma","year":"2026","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2026.112199_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"4","key":"10.1016\/j.ejso.2026.112199_bib20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/jso.24678","article-title":"The prognostic utility of the \"Tumor Burden Score\" based on preoperative radiographic features of colorectal liver metastases","volume":"116","author":"Sasaki","year":"2017","journal-title":"J Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2026.112199_bib21","first-page":"0","article-title":"Oncological resectability criteria for hepatocellular carcinoma in the era of novel systemic therapies: the Japan liver cancer association and Japanese society of hepato-biliary-pancreatic surgery expert consensus statement 2023","volume":"13","author":"Akahoshi","year":"2024","journal-title":"Liver Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2026.112199_bib22","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/hep.31840","article-title":"Mechanistic rationales guiding combination hepatocellular carcinoma therapies involving immune checkpoint inhibitors","volume":"74","author":"Cheu","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejso.2026.112199_bib23","first-page":"327","article-title":"Hepatocellular carcinoma and the role of liver transplantation: an update and review","volume":"13","author":"Sequeira","year":"2025","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"10.1016\/j.ejso.2026.112199_bib24","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/liv.15487","article-title":"Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab","volume":"43","author":"Campani","year":"2023","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.ejso.2026.112199_bib25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3390\/medicina60050692","article-title":"Prognostic role of basal serum alpha-fetoprotein in patients with hepatocellular carcinoma suitable for curative treatment","volume":"60","author":"Mazza","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"5","key":"10.1016\/j.ejso.2026.112199_bib26","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/jso.26091","article-title":"Recurrence beyond the Milan criteria after curative-intent resection of hepatocellular carcinoma: a novel tumor-burden based prediction model","volume":"122","author":"Tsilimigras","year":"2020","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.112199_bib27","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000505692","article-title":"Exploratory analysis to identify candidates benefitting from combination therapy of transarterial chemoembolization and sorafenib for first-line treatment of unresectable hepatocellular carcinoma: a multicenter retrospective observational study","volume":"9","author":"Wang","year":"2020","journal-title":"Liver Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2026.112199_bib28","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000522547","article-title":"Final results of TACTICS: a randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Liver Cancer"},{"issue":"12","key":"10.1016\/j.ejso.2026.112199_bib29","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/S1470-2045(25)00543-1","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study","volume":"26","author":"Qin","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.112199_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102622","volume":"72","author":"Jin","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.ejso.2026.112199_bib31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(25)00190-1","article-title":"Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial","volume":"26","author":"Zhou","year":"2025","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.112199_bib32","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","article-title":"Global epidemiology and genetics of hepatocellular carcinoma","volume":"164","author":"Toh","year":"2023","journal-title":"Gastroenterology"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326008188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326008188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:29:38Z","timestamp":1791912578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326008188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S0748798326008188"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112199","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Value of tumor burden score combined with alpha-fetoprotein stratification in transarterial chemoembolization plus tyrosine kinase inhibitors and immune checkpoint inhibitors as triple conversion therapy for patients with initially unresectable hepatocellular carcinoma: a multicenter retrospective study (GUIDANCE010)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112199"}}